프로티나
Financials
Valuation Metrics
프로티나's Market Cap is ₩3909B. Ranked #547 of 2,421 in KR market (top 23%), #215 of 1,640 on KOSDAQ (top 13%), #58 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 390.90B KRW | KR#547/2,421 Sec#58/231 |
| Revenue | 2.95B KRW | KR#2,372/2,421 Sec#207/231 |
| Net Income | -9.01B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 31.75B KRW | KR#2,328/2,421 Sec#221/231 |
| Net Assets | 28.37B KRW | KR#2,191/2,421 Sec#199/231 |
| Employees | 15 | KR#2,274/2,421 Sec#214/231 |
| Value | ||
| P/B | 13.78x | KR#2,386/2,421 Sec#216/231 |
| P/S | 132.47x | KR#2,396/2,421 Sec#213/231 |
| FCF Yield | -2.34% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -31.76% | KR#2,197/2,421 Sec#179/231 |
| ROA | -28.38% | KR#2,308/2,421 Sec#198/231 |
| Op. Margin | -385.23% | KR#2,357/2,421 Sec#197/231 |
| Financial Health | ||
| Debt Ratio | 11.91% | KR#186/2,421 Sec#35/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -9.16B KRW | KR#1,680/2,421 Sec#143/231 |
| Cash | 8.79B KRW | KR#1,764/2,421 Sec#156/231 |
| Current Ratio | 15.15x | KR#49/2,421 Sec#16/231 |
| Performance | ||
| 1Y Return | 2.03% | KR#692/2,421 Sec#44/231 |
| 1M Return | 2.77% | KR#951/2,421 Sec#68/231 |
| From 52W High | -70.69% | KR#2,206/2,421 Sec#191/231 |
| 1Y MDD | -85.81% | KR#2,374/2,421 Sec#226/231 |
| Trading | ||
| Volume | 115,746 shares | KR#715/2,421 Sec#66/231 |
| Trading Value | 4.17B KRW | KR#402/2,421 Sec#38/231 |
| Foreign Own. | 2.51% | KR#1,454/2,421 Sec#137/231 |
| Per Share | ||
| EPS | -812 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,555 KRW | KR#1,942/2,421 Sec#153/231 |
Company Info
Proteina Co., Ltd. is dedicated to pioneering technology for characterizing protein-protein interactions (PPIs). Their innovative approach enables the direct visualization of specific proteins to confirm the real-time activation of cancer signaling pathways. This capability helps predict drug efficacy and, crucially, empowers medical professionals to select optimal inhibitors by identifying bypass pathways that contribute to drug resistance. The company further offers a distinct single-molecule protein interaction detection platform, designed for in-depth analysis of protein and PPI information. Founded in 2015, Proteina Co., Ltd. is headquartered in Seoul, South Korea.